Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients...

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is associated with elevated hemostatic risk factors for cardiovascular disease.
• Key risk factors include fibrinogen, von Willebrand factor (VWF), factor (F)VIIa, d-dimer, and plasminogen activator inhibitor-1 (PAI-1).

Purpose of the Study:

• To investigate the impact of aggressive versus standard-dose atorvastatin on cardiovascular hemostatic risk factors in T2DM patients.
• To determine dose-dependent effects of atorvastatin on specific biomarkers.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted.
• 217 patients with T2DM and dyslipidemia received atorvastatin (10 mg or 80 mg) or placebo for 30 weeks.
• Hemostatic cardiovascular risk factors were assessed.

Main Results:

• Atorvastatin demonstrated dose-dependent reductions in d-dimer (7.4% at 10 mg, 8.5% at 80 mg) and PAI-1 antigen levels (9.0% at 10 mg, 18% at 80 mg).
• No significant influence of atorvastatin was observed on fibrinogen, VWF, tissue-type plasminogen activator, or FVIIa levels.
• P-values for trend were 0.004 for d-dimer and 0.021 for PAI-1.

Conclusions:

• Atorvastatin effectively and dose-dependently improved levels of d-dimer and PAI-1 in patients with T2DM.
• These findings suggest a potential benefit of atorvastatin in managing cardiovascular risk associated with hemostatic abnormalities in T2DM.
• Further research may explore the clinical implications of these hemostatic improvements.